Your browser doesn't support javascript.
loading
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.
Cairns, P; Polascik, T J; Eby, Y; Tokino, K; Califano, J; Merlo, A; Mao, L; Herath, J; Jenkins, R; Westra, W; Rutter, J L; Buckler, A; Gabrielson, E; Tockman, M; Cho, K R; Hedrick, L; Bova, G S; Isaacs, W; Koch, W; Schwab, D; Sidransky, D.
Affiliation
  • Cairns P; Department of Otolaryngology Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205-2196, USA.
Nat Genet ; 11(2): 210-2, 1995 Oct.
Article in En | MEDLINE | ID: mdl-7550353
ABSTRACT
Many tumour types have been reported to have deletion of 9p21 (refs 1-6). A candidate target suppressor gene, p16 (p16INK4a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.
Subject(s)
Search on Google
Database: MEDLINE Main subject: Genes, Tumor Suppressor / Chromosome Deletion / Neoplasms Limits: Female / Humans / Male Language: En Year: 1995 Type: Article
Search on Google
Database: MEDLINE Main subject: Genes, Tumor Suppressor / Chromosome Deletion / Neoplasms Limits: Female / Humans / Male Language: En Year: 1995 Type: Article